Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.160 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 07, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 07, 2023

It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.

Via InvestorPlace

Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 07, 2023

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 06, 2023

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Coherus BioSciences's Earnings: A Preview ↗

November 03, 2023

Via Benzinga

Analyst Expectations for Coherus BioSciences's Future ↗

October 23, 2023

Via Benzinga

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

November 06, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗

November 04, 2023

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...

Via Talk Markets

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

November 03, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences to Participate at Upcoming November Investor Conferences

November 02, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

4 Analysts Have This to Say About Coherus BioSciences ↗

September 26, 2023

Via Benzinga

BP, V.F. Corporation, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 31, 2023

U.S. stock futures traded mostly higher this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

October 30, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Stock Soared Today ↗

October 30, 2023

Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know.

Via The Motley Fool

What's Going On With Coherus BioSciences Stock? ↗

October 30, 2023

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for

Via Benzinga

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket ↗

October 30, 2023

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

October 30, 2023

It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 27, 2023

Via Benzinga

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

October 27, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

October 24, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Stock Popped Today ↗

October 05, 2023

Coherus resubmitted a license application for a key product today. Here's what investors need to know.

Via The Motley Fool

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

October 05, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

October 04, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

October 02, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

September 27, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients ↗

September 25, 2023

The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of...

Via Benzinga

Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 25, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.